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Research
Hazardous air pollutants (HAPs, or air 
toxics) are pollutants known to cause can-
cer or other serious health effects as well as 
environmental effects. The majority of air 
toxics originate from human-made sources, 
including mobile sources (e.g., automobiles) 
and stationary sources (e.g., factories). Under 
the Clean Air Act Amendments (CAAA) of 
1990, the U.S. Environmental Protection 
Agency (EPA) regulates 187 HAPs from both 
stationary and mobile sources. HAPs are 
distinct from the criteria pollutants, such as 
ozone, carbon monoxide, particulate matter, 
sulfur oxides, nitrogen dioxide, and lead, that 
generally have much more extensive informa-
tion about health effects and are regulated 
under other CAAA authorities. For major 
stationary sources, the act requires the EPA to 
set maximum achievable control technology 
(MACT) standards to reduce HAP emissions 
(CAAA 1990). After setting these standards, 
the U.S. EPA evaluates the residual risks from 
exposure to HAPs to determine if further 
regu  lation is warranted. For smaller stationary 
sources of HAPs (e.g., gasoline distribution, 
auto body refinishing), the EPA is required 
to set technology standards, which are known 
as generally available control technology 
(GACT). To control mobile source air toxics, 
the EPA is required to set technology and fuel 
standards for motor vehicles. Since 1990, the 
EPA has made significant progress in issuing 
standards under the CAAA to reduce emis-
sions of air toxics both from stationary and 
mobile sources. To determine the impact 
of these efforts, Section 812 of the CAAA 
requires the EPA to perform periodic, com-
prehensive analyses of the costs and total 
benefits of programs implemented pursu-
ant to the Clean Air Act (CAA 1970). The 
EPA has completed two of these analyses: a 
retrospective analysis in 1997 of the origi-
nal CAA covering the period from 1970 to 
1990 (U.S. EPA 1997) and a prospective 
analysis in 1999 of the incremental costs and 
benefits of the CAAA from 1990 to 2010 
(U.S. EPA 1999). These and other studies 
have highlighted many of the challenges in 
estimating the benefits of reducing air toxics 
emissions.
Challenges for Air Toxics 
Benefits Assessment
Benefits analysis for any environmental 
regulation requires estimating how individuals 
and regulated entities respond to the regu  lation, 
as well as estimating fate, transport, exposure, 
and effects of environmental chemicals. Thus, 
this type of assessment is subject to significant 
limitations and uncertainties. The U.S. EPA 
estimates benefits in regulatory impact analyses 
(RIAs) for rules that have a significant impact 
on the economy, typically based on a sequen-
tial analysis of emissions estimation modeling, 
air quality and exposure modeling, health and 
environmental effects estimation, and economic 
valuation. For major air toxics rules, the EPA 
has estimated benefits based on reductions in 
fine particulate matter (referred to as PM2.5) 
or ozone rather than those based directly on 
reductions of air toxics [Fann et al. 2009; 
Krupnick 2006; National Research Council 
(NRC) 2002)]. To estimate the benefits of 
reducing air toxics directly, there is a need for 
both near-term and long-term benefits assess-
ment specific to the issues of air toxics reduc-
tion. Challenges related specifically to benefits 
Address correspondence to M.R. Gwinn, EICG/
NCEA/ORD/USEPA, 1200 Pennsylvania Ave., 
NW, Mail Code 8623-P, Washington, DC 20460 
USA. Telephone: (703) 347-8565. Fax: (703) 347-
8692. E-mail: gwinn.maureen@epa.gov.
Special thanks for the contributions from present-
ers including H. Roman, T. Woodruff, V. Benignus, 
L. Zeise, R. Walsh, S. Banzhaf, J. Levy, K. Viscusi, 
A. Krupnick, M. Cropper, and D. Hattis.
This document summarizes the conclusions from 
the workshop—Estimating the Benefits of Reducing 
Hazardous Air Pollutants (HAPs), which was spon-
sored by the U.S. Environmental Protection Agency 
[EPA; Office of Air and Radiation (OAR), Office of 
Policy, Economics and Innovation (OPEI), and the 
Office of Research and Development (ORD)] with 
contract support from ICF International.
The views expressed in this document are those 
of the authors and do not necessarily represent the 
views and policies of the U.S. EPA.
The authors declare they have no actual or potential 
competing   financial interests.
Received 20 May 2010; accepted 4 October 2010.
Meeting Report: Estimating the Benefits of Reducing Hazardous Air 
Pollutants—Summary of 2009 Workshop and Future Considerations
Maureen R. Gwinn,1 Jeneva Craig,2 Daniel A. Axelrad,3 Rich Cook,4 Chris Dockins,3 Neal Fann,5 Robert Fegley,6 
David E. Guinnup,5 Gloria Helfand,4 Bryan Hubbell,5 Sarah L. Mazur,6 Ted Palma,5 Roy L. Smith,5 
John Vandenberg,7 and Babasaheb Sonawane1
1National Center of Environmental Assessment, Office of Research and Development, 2Office of Policy Analysis and Review, Office of 
Air and Radiation, and 3National Center for Environmental Economics, Office of Policy, Economics and Innovation, U.S. Environmental 
Protection Agency, Washington, DC, USA; 4Office of Transportation and Air Quality, Office of Air and Radiation, U.S. Environmental 
Protection Agency, Ann Arbor, Michigan, USA; 5Office of Air Quality Planning and Standards, Office of Air and Radiation, U.S. 
Environmental Protection Agency, Research Triangle Park, North Carolina, USA; 6Office of Science Policy, Office of Research and 
Development, U.S. Environmental Protection Agency, Washington, DC, USA; 7National Center of Environmental Assessment, Office of 
Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina, USA
Ba c k g r o u n d: Quantifying the benefits of reducing hazardous air pollutants (HAPs, or air toxics) 
has been limited by gaps in toxicological data, uncertainties in extrapolating results from high-dose 
animal experiments to estimate human effects at lower doses, limited ambient and personal expo-
sure monitoring data, and insufficient economic research to support valuation of the health impacts 
often associated with exposure to individual air toxics.
oBjectives: To address some of these issues, the U.S. Environmental Protection Agency held 
the Workshop on Estimating the Benefits of Reducing Hazardous Air Pollutants (HAPs) in 
Washington, DC, from 30 April to 1 May 2009.
discussion: Experts from multiple disciplines discussed how best to move forward on air toxics 
benefits assessment, with a focus on developing near-term capability to conduct quantitative bene-
fits assessment. Proposed methodologies involved analysis of data-rich pollutants and application 
of this analysis to other pollutants, using dose–response modeling of animal data for estimating 
benefits to humans, determining dose-equivalence relationships for different chemicals with similar 
health effects, and analysis similar to that used for criteria pollutants. Limitations and uncertainties 
in economic valuation of benefits assessment for HAPS were discussed as well.
co n c l u s i o n s : These discussions highlighted the complexities in estimating the benefits of reduc-
ing air toxics, and participants agreed that alternative methods for benefits assessment of HAPs 
are needed. Recommendations included clearly defining the key priorities of the Clean Air Act air 
toxics program to identify the most effective approaches for HAPs benefits analysis, focusing on 
susceptible and vulnerable populations, and improving dose–response estimation for quantification 
of benefits.
key w o r d s : air toxics, benefit analysis, economic valuation, exposure modeling, hazardous air 
pollutants. Environ Health Perspect 119:125–130 (2011).  doi:10.1289/ehp.1002468 [Online 
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analysis for air toxics include uncertainties in 
emissions information, air quality and exposure 
modeling, effects estimation, and economic 
valuation, as well as distribution considerations. 
These challenges are described below.
Emissions. The U.S. EPA maintains an 
inventory of emissions for most of the 187 
air toxics, although the data are less reli-
able than the inventory for the six criteria 
pollutants. The National Emissions Inventory 
is updated every 3 years and provides infor-
mation from major stationary sources, smaller 
area stationary sources, on-road and non-
road mobile sources, and other sources (e.g., 
wildfires). Unlike criteria pollutants, report-
ing air toxics is not mandatory and varies by 
state. Therefore, some of these area sources 
have limited emissions information and 
are estimated through modeling. The U.S. 
EPA also publishes an annual Toxics Release 
Inventory (TRI) that requires facilities to 
report releases of 666 chemicals and chemical 
categories (including most of the air toxics) to 
air, land, and water (U.S. EPA 2010).
Air quality and exposure modeling. The 
relationship between air emissions of toxics 
and human exposure is complex and often 
difficult to estimate. Air toxics vary widely 
in their sources, photochemical reactiv-
ity, and scale of spatial variability. In addi-
tion, exposure assumptions may differ 
significantly from actual individual exposures. 
For example, the typical assumption that 
people are exposed to the air outside their 
residences for 24 hr a day for a lifetime is 
used to simplify population analysis but intro-
duces error in the exposure estimates, par-
ticularly when considered at the individual 
level (Isakov et al. 2009). Indoor sources may 
also be important components of individual 
exposure to air toxics and may be affected 
by emissions regulations (e.g., lawn and gar-
den equipment in attached garages) (U.S. 
EPA 2007a; Weisel et al. 2002). Exposure 
assessment of average or cumulative expo-
sures may miss significant acute exposures. 
The EPA National Air Toxics Assessment 
(NATA; U.S. EPA 2009b), which is cur-
rently available to the public with 2002 
data, estimates ambient concentrations at 
the census-tract level (large scale) for mobile 
and area source emissions and at the census-
block level (small scale) for major stationary 
source emissions]. The NATA then estimates 
inhalation exposure at the census-block level, 
which takes into account ambient exposures 
in various microenvironments, and calculates 
lifetime inhalation risks of cancer and non-
cancer health effects. The assessment does not 
provide estimates of ingestion risks that are 
important for certain air toxics such as mer-
cury and lead (U.S. EPA 2001, 2009b).
Health and environmental effects esti-
mation. The list of HAPs to be regulated by 
the EPA is enumerated in the CAAA. For 
many chemicals on the list, the information 
on potential health effects is so limited that 
quantitative benefits analysis is not feasible 
(Goldstein and Carruth, 2003). This lack of 
information is in contrast to the criteria air 
pollutants for which there is extensive human 
exposure or epidemiological data on the health 
effects at ambient-exposure levels. For most of 
the air toxics, the available health information 
is based on animal studies. Therefore, reasoned 
assumptions about how these data relate to 
potential human health hazards are needed. 
The relatively smaller epidemiological data 
set for air toxics is based mostly on relatively 
high occupational exposures (e.g., for ben-
zene) and has several limitations. These limita-
tions include lack of information on multiple 
health end points across the life stages, suscep-
tible populations, and differentially exposed 
groups. The potential for noncancer effects 
from exposure to air toxics is evaluated by 
comparing HAP concentrations with the ref-
erence concentration (RfC), which is a point 
estimate of the level expected to be without 
appreciable effects from chronic exposure 
in the population. The RfC definition does 
not incorporate any quantitative expression 
of risk. Furthermore, uncertainties related to 
quantitative values of risk for both cancer and 
noncancer health effects are rarely explored, 
understood, and characterized. For these and 
other reasons, characterizing the health effects 
of air toxics at ambient levels can be sub-
ject to a very high level of uncertainty; thus, 
using these health effects in economic ben-
efits assessment is difficult. The recent NRC 
report, Science and Decisions: Advancing Risk 
Assessment, has provided recommendations 
applicable to issues related to benefits assess-
ment of air toxics, including dose–response 
assessment, analysis of uncertainty and vari-
ability, default selection and use, and cumula-
tive risk assessment (NRC 2009).
Economic valuation. Standard economic 
analysis for pollution reduction starts with 
estimates of reduced mortality and morbidity 
effects (and other nonhealth effects as appro-
priate) (U.S. EPA 2000). Currently, benefits 
are estimated by aggregating reduced mor-
tality risks to an expected number of deaths 
avoided, which are then multiplied by an 
aggregate willingness-to-pay (WTP) figure 
called the value of a statistical life (VSL). 
Reduced morbidity benefits are estimated 
similarly, when dose–response information 
is available to estimate the expected cases 
avoided, which are then multiplied by either 
an estimate of WTP to avoid the illness or an 
estimate of the cost associated with the treat-
ment of that illness. Applying these methods 
to air toxics requires estimates of the mortality 
and morbidity effects. In the absence of these 
estimates, the benefits of toxics reduction 
may not be included in the analysis, result-
ing in a default assumption of zero benefits. 
In addition, people may be willing to pay for 
reducing toxics, even when the data on their 
effects are limited, to avoid perceived risks. 
The standard approach does not incorporate 
this willingness to pay.
Efficiency versus distributional consid-
erations. Regulations focused on air toxics 
seek not only to improve overall public health 
but also to address disproportionate risk in 
a segment of the population. The U.S. EPA 
must issue additional standards for sources 
after MACT if necessary to protect public 
health with an adequate margin of safety 
(CAAA 1990). In these cases, protecting the 
most exposed individuals rather than maxi-
mizing risk reduction over the entire exposed 
population may be the guiding objective. In 
fact, the CAAA specifically refer to reducing 
lifetime excess cancer risks to individuals most 
exposed to emissions from a source. Existing 
cost–benefit techniques are not intended to 
address tradeoffs between net benefits and 
distributional and equity considerations (Levy 
et al. 2009).
Focus of 2009 Workshop
Discussions regarding best practices for 
estimating human health benefits from 
reductions in exposure to air toxics have 
been ongoing for years, but no consensus 
has been reached on methods that could be 
implemented for a broad selection of these tox-
ics. Specifically, benefits analyses are inhibited 
by the lack of data relating exposures to health 
effects, uncertainties in extrapolating results 
from high-dose animal experiments to estimate 
human effects at lower doses, limited monitor-
ing of ambient and personal exposure data, 
and insufficient economic research to support 
valuation of the health impacts often associated 
with exposure to individual air toxics.
Recognizing the uncertainties and research 
needs for many aspects of benefits assess-
ment of reductions in air toxics, the U.S. EPA 
sponsored a workshop to explore the key issues 
related to health and environmental effects, 
economic valuation, and equity considerations 
(U.S. EPA 2009c). Highlights from these pre-
sentations are summarized below.
Lessons learned from recent research. Risk 
assessors have been working on alternative 
ways to assess the benefits related to reducing 
air toxics. Workshop participants explored four 
case studies that used alternative approaches. 
These case studies focused on approaches that 
could be implemented with existing informa-
tion, could potentially be conducted at a rea-
sonable cost, were the least likely to introduce 
bias, and were the most scientifically defen-
sible. They included developing methodolo-
gies for data-rich HAPs (e.g., benzene) with 
a broader application to other HAPs, using Benefit analysis of HAPS reduction
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animal data to estimate a dose–response curve 
for adverse health effects in humans (e.g., 
acrolein), using dose-equivalent relationships 
between chemicals with similar adverse health 
effects (e.g., toluene), and analyzing HAPs 
similar to that performed for criteria pollutants 
(e.g., lead) (Table 1). In addition to these four 
case studies, the workshop participants con-
sidered environmental quality in relation to 
changing community composition and equity 
tradeoffs. These alternative methodologies and 
key issues suggest potential options for analyz-
ing benefits from air toxics reductions and 
highlight continued challenges in the field. 
The case studies are described in more detail 
below and summarized in Table 1.
Benefits of benzene reductions in 
Houston, Texas. In a case study designed to 
estimate the benefits of reducing benzene for 
a three-county area around Houston, Texas, 
scientists quantified changes in individual 
risk using air quality and exposure models 
and translated these changes into monetized 
benefits [Industrial Economics, Inc. (IEc) 
2009]. Benzene was used as an example of 
a data-rich air toxic pollutant to develop a 
methodology that could then be applied more 
widely. The case study modeled benzene expo-
sures and health impacts using two scenarios: 
One assumed that all regulatory programs 
affecting benzene emissions were enacted in 
response to CAAA, and one assumed that 
no additional controls were implemented 
beyond the requirements existing in 1990. 
The difference in emissions between these two 
scenarios provided the basis for estimating 
the health benefits related to the reduction of 
benzene concentrations in Houston, Texas, 
because of the CAAA. As part of the Houston 
study, scientists examined the incidence of 
leukemias to estimate the health benefits from 
reductions in benzene exposure. The results 
demonstrated a decrease in fatal and nonfatal 
leukemias between 1990 and 2020. To meas-
ure the health outcomes, researchers used the 
VSL to monetize the avoided fatal leukemias 
and the WTP to monitize the nonfatal leuke-
mias. This case study represents the uncom-
mon situation where relatively complete 
information is available (e.g., human health 
evidence, air quality monitoring data) to esti-
mate the health effects of air toxics and the 
benefits of reducing them. However, uncer-
tainties and limitations of the approach used 
in this case study include large variations in the 
results because of the sensitivity of the model 
to unputs; for example, varying dose–response 
estimates or alternative cessation lags; the pos-
sibility that other health end points related 
to benzene exposure were not examined; and 
the limited age groups studied in the cohort. 
The approach used in the Texas case study was 
data- and resource-intensive and may be dif-
ficult to expand to other air toxics.
Estimating risk from acrolein. The 
analysis of acrolein risks for respiratory 
effects examined the applicability of using 
dose–response modeling of animal data to 
estimate the benefits to humans. Using data 
from a study in rats exposed to acrolein (Costa 
et al. 1986), Woodruff et al. (2007) evaluated 
two end points that are indicators of reducded 
lung function. These end points were selected 
based on the presence of a significant dose-
related trend, on data that was amenable to 
modeling, and on the relevance to changes in 
lung function in humans. Acrolein concentra-
tions from the rat study were converted into 
human equivalent concentrations using U.S. 
EPA standard methods (U.S. EPA 2003), and 
the data for each end point were modeled 
using EPA Benchmark Dose Software (U.S. 
EPA 2009a). Increased risk was then esti-
mated as the proportion of the population 
that would experience a change in adverse 
lung function, considering ambient concen-
trations in the United States estimated in 
NATA. This case study represents the more 
typical situation where relatively little infor-
mation is available (e.g., animal toxicology 
data) to estimate air toxics health effects and 
the benefits of reducing them.
Cost of neurobehavioral effects of   toluene 
exposure. Benignus et al. (2005) estimated 
the economic benefits of reducing expo-
sure to toluene by comparing these neuro-
behavioral effects with those of well-  studied 
ethanol ingestion. The investigators used 
dose-equivalent relationships to estimate the 
costs of intoxication. Because many air tox-
ics have effects on the nervous system that 
are very similar to those of ethanol, Benignus 
et al. (2005) quantified behavioral effects 
of toluene and ethanol in human subjects 
using a meta-analysis of studies from the 
peer-reviewed literature that measured the 
effects of the chemicals on choice reaction 
time (CRT). CRT is a two-choice reaction 
Table 1. Overview of case studies that explored various methodologies for benefits analysis of regulating air toxics.
Chemical name
Dose–response 
data
Health end point(s) 
analyzed
Methods for risk 
evaluation
Methods for 
valuation
Size of benefit/
potential utility Uncertainties Reference
Benzene Human 
epidemiological 
studies 
(occupational 
cohort)
Leukemias (fatal 
and nonfatal)
Life table approach VSL for fatal 
leukemias; 
approximation 
of willingness to 
pay for nonfatal 
leukemias
Model demonstrated 
percent reduction in 
risk by 2020 from 72 
to 98% depending on 
county
Model sensitive to 
inputs; only quantified 
leukemias and not 
other health effects; 
low-dose extrapolation 
issues
IEc 2009
Acrolein Analysis of 
existing animal 
studies with 
dose conversion 
to human 
equivalents
Respiratory effects 
(noncancer)
Dose–response 
functions combined 
with modeled ambient 
acrolein concentrations 
to estimate risks of 
adverse effects
Not carried out in 
this study; further 
analysis needed to 
relate respiratory 
outcomes 
observed in 
animals to likely 
human effects
Method used animal 
data to inform 
benefits of reduction 
in exposure in human 
populations
Assumptions based on 
low-dose extrapolation 
and human 
interpretation of end 
point (adverse effects 
as general indicators 
of potential human 
lung function changes)
Woodruff 
et al. 2007
Toluene Meta-analysis 
of human 
epidemiology 
studies on 
toluene and 
ethanol effects
Neurobehavioral 
effects
Dose-scaling comparison 
for acute effects of 
toluene exposure with 
those of ethanol intake
Effect of toluene 
scaled to that 
of ethanol; used 
costs of ethanol 
intoxication 
(e.g., automobile 
crashes)
Comparison with 
another toxicant with 
the same mechanism 
of action that has 
been monetized can 
yield a quantitative 
benefits estimate
Assumptions needed for 
mechanisms of both 
toxicants and dose–
response comparisons
Benignus 
et al. 2005
Lead Human 
epidemiology 
studies
IQ Model changes in lead 
air quality for the 
exposed population and 
translated these into 
changes in blood lead
Present value of 
lifetime loss in 
earnings per IQ 
point lost
Provide a credible 
estimate of the 
human health benefits 
of attaining alternate 
lead NAAQS
Uncertainties in 
air-lead to blood-
lead relationship; 
valuation method had 
substantial limitations
U.S. EPA 
2008
Abbreviations: IQ, intelligence quotient; NAAQS, National Ambient Air Quality Standards.Gwinn et al.
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time test that is useful for assessing general 
alertness and motor speed. Models were used 
to estimate internal doses of ethanol and tol-
uene associated with effects on CRT from 
exposure parameters provided in the pub-
lished literature. This case study represents the 
scenario where relatively complete informa-
tion is available for one chemical (ethanol) 
to estimate air toxics health effects and assess 
the benefits of reducing the effects for other 
chemicals with less information, such as tolu-
ene. The uncertainties of this method include 
the quality of the exposure data and the extent 
of the mechanistic similarity between the 
observed effects of the two compounds.
Human health benefits assessment for 
lead standards. The final case study was an 
analysis of the human health and welfare 
benefits associated with attaining alterna-
tive levels for the lead National Ambient 
Air Quality Standards (NAAQS). This case 
study was part of the RIA to estimate the 
expected benefits and costs of attaining a new 
NAAQS (U.S. EPA 2008). This was an exam-
ple of methodologies that can be applied for 
environmental chemicals with extensive epi-
demiological data and highlighted the com-
plications introduced by some key data gaps 
that may exist even for data-rich chemicals. 
The U.S. EPA quantified the monetary value 
of lead-associated changes in intelligence 
quotient (IQ). This analysis followed four 
basic steps. First, the U.S. EPA estimated the 
change in ambient lead resulting from attain-
ment of alternate NAAQS levels, relative to 
baseline ambient lead levels in 2016. Then the 
EPA applied air-to-blood ratios to quantify the 
change in blood lead as a function of exposure 
to ambient lead. The third step was to apply 
relevant epidemiological studies to quantify 
the population-level change in IQ points. 
Finally, the EPA monetized the change in IQ 
points by using economic valuation functions 
to measure the foregone lifetime earnings per 
lost IQ point. As part of a sensitivity analysis 
to test the importance of key model inputs, 
the analysis concluded that total benefits 
were highly sensitive to the air quality esti-
mates, the discount rate, and the air-to-blood 
ratio. The U.S. EPA approach to estimating 
ambient lead-related benefits may serve as a 
useful model for future analyses of air toxics 
with noninhalation exposure pathways.
Additional presentations related to air 
toxics benefits analysis. Two additional 
presentations addressed distributional con-
siderations for benefits analysis. The first, an 
analysis of changing environmental quality on 
community composition, provided a simple 
model analysis of the relationship between 
TRI emissions and low-income communi-
ties and showed that reducing exposure in 
these communities would not necessarily 
have favorable distributional effects (Walsh 
and Banzhaf 2009). Using the example of 
the impact of TRI emissions reductions in 
California, it was concluded that estimating 
the true effects of reductions of air toxics on 
local communities requires a more thorough 
understanding of the relationships among 
environmental improvements, real estate 
markets, and demographics. This study under-
scored the role of sociological factors in air 
toxics benefits analyses. In the second study, 
Levy et al. (2007) highlighted recent research 
that evaluated the efficiency–equality tradeoffs 
in health benefits analysis; they used a model-
ing framework that may have potential impli-
cations for air toxics emissions reduction. 
These tradeoffs are between the magnitude of 
(efficiency) and the distribution of the health 
benefits (equality). The challenge in their anal-
ysis was to find a simple, meaningful indicator 
that could capture the distribution of the ben-
efits of pollution control from a source or set 
of sources. This analytical framework could 
be applied to capture the distribution of base-
line risk from air toxics and the distribution 
of risk postcontrol. For this framework to 
be useful, multiple well-defined and realistic 
control scenarios would have to be developed. 
This study demonstrated that approaches for 
incorporating equity considerations may have 
applications for air toxics benefits assessment.
Three particular issues relating specifi-
cally to the estimation of air toxics benefits 
reduction were also explored in more depth: 
valuing reductions in individual risks, WTP 
for reducing air toxics, and alternatives to 
pollutant-by-pollutant dose–response estima-
tion. Valuing large reductions in individual 
mortality risks focused on evaluating whether 
the magnitude of estimated risks being 
reduced requires new valuation methods or 
adjustments in current values to reflect the 
extent of risk changes. Labor market estimates 
of VSL provide the wage–risk tradeoffs for 
small risks. The degree to which these values 
are applicable to a particular benefits analysis 
depends, in part, on the magnitude of the risk 
reduction (Viscusi 2009).
WTP analysis for the large number of 
air toxics creates a challenge when using a 
damage-function approach to assess benefits, 
as it requires a dose–response relationship for 
each HAP. Key issues for valuation of reduced 
air toxics risks include what benefits to value, 
whether altruistic values should be included, 
whether to value subjective or objective risks, 
and whether valuation results could be applied 
to different policies (Cropper and Krupnick 
2009). Ideally, a WTP approach would sepa-
rate risk assessment from valuation.
A major issue for assessing HAPs is that 
the measures for estimating noncancer health 
risks (e.g., RfC) do not lend themselves to 
quantification of risk reductions for bene-
fit analysis (Hattis et al. 2002). Methods to 
overcome the barriers to the quantification of 
noncancer health risks were discussed. More 
specifically, research that focuses on estimat-
ing risks without extensive chemical-specific 
toxicity information, creating a framework for 
understanding and quantifying the uncertain-
ties created by missing data that can be the 
basis for value-of-information analysis, and 
facilitating comparisons and priority setting 
for controlling exposure to different air toxics 
is needed (Hattis and Lynch 2009).
Road map on benefits assessment for 
air toxics. Air toxics benefits assessment has 
focused on a limited number of pollutants 
based on available dose–response and exposure 
information, generally on a worst-first basis. 
One main purpose of the workshop was to 
discuss other near-term benefits assessment 
options as laid out in the draft roadmap (U.S. 
EPA 2009c). Although the roadmap also listed 
many areas for long-term research, the work-
shop participants focused more on the five 
near-term options in the roadmap:
•Qualitatively assess air toxics reduction benefits 
with no attempt at quantification. This 
approach gives risk assessors the flexibil-
ity to make a qualitative case for air toxics 
control, while not exposing the analysis (or 
the regulation it supports) to the drawbacks 
and uncertainties associated with estimating 
benefits in quantitative terms from air toxics 
reductions based on the current state of the 
science. A concern with this approach is that 
some will assume that benefits are negligible 
rather than unquantifiable, and therefore 
the value of the air toxics program and its 
regulations may be underestimated.
• Use the existing frameworks to sketch out min-
imum benefits from a national perspective. 
This approach would build on work that is 
ongoing regarding benefits analysis looking 
pollutant by pollutant. For example, risk 
assessors could use the benzene methodology 
to estimate benefits of reducing benzene 
exposure on a wider geographic scale and 
to estimate benefits of reducing other 
carcinogens with human data on inhalation 
exposures (e.g., 1,3-butadiene); to adapt the 
acrolein methodology to estimate effects 
of other priority inhalation noncancer 
pollutants (e.g., manganese); and to use the 
lead methodology to estimate benefits from 
other noninhalation risks (e.g., mercury). 
This approach would build on peer-  reviewed 
work and provide an assessment of fatal and 
nonfatal cancer effects for certain pollut-
ants, using standard benefits methods. It 
could also focus on the pollutants that risk 
assessors believe are driving the majority 
of the risks from a national perspective. 
However, this approach would not address 
some of the challenges laid out earlier, such 
as possible underestimation of health effects 
from hot spots or short-term exposures and Benefit analysis of HAPS reduction
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effects of interactions among pollutants on 
adverse health outcomes in a population 
across life stages and/or in disproportion-
ately exposed populations.
• Use NATA or other existing modeling tools to 
pursue national or regional or local analysis 
focusing on reduction of individual risk lev-
els. This approach has been used with the 
1999 NATA framework as part of the 2007 
Mobile Source Air Toxics Rule (U.S. EPA 
2007b). In that rule, air toxics modeling was 
done for 1999 and several future years, with 
and without controls. The 1999 NATA was 
modified to account for the pollutant gradi-
ents near roads, analyzing 19 mobile source 
air toxics. The analysis included estimates 
of monetized benefits from PM reductions 
that also occurred as a result of the rule but 
did not monetize reductions in toxics risk. 
This is primarily because the NATA frame-
work is not adequate for extrapolation to 
incidence estimations or benefits assessment 
(U.S. EPA 2001, 2007b). The model has 
several limitations, including the inability 
to estimate specifics for different age groups 
and the lack of accounting for indoor 
sources and potentially important exposure 
scenarios. The strengths of this approach 
include the ability to examine multiple 
pollutants at the same time and look across 
various geographic areas to estimate impacts 
on individual risk levels.
• Estimate benefits of air toxics emissions reduc-
tions in conjunction with the criteria air 
pollution program. Many regulations and 
implementation actions to meet criteria air 
pollution goals affect the same sources that 
emit significant air toxics. In some cases, the 
emissions that contribute to ambient con-
centrations of ozone, PM, and other criteria 
air pollutants are also air toxics. To date, 
with the significant exception of mobile 
source regulations of volatile organic com-
pound and PM precursor emissions, the U.S. 
EPA has not assessed the air toxics impacts 
of the criteria air pollutant programs. 
Because these criteria pollutant programs are 
often very broad in nature, covering many 
sources and geographic areas, the cumula-
tive impact on air toxics may be large. At 
the very least, risk assessors could estimate 
changes in population-weighted concentra-
tions of air toxics, even in the absence of 
appropriate   concentration–response func-
tions linking concentrations with health end 
points. This approach would provide a con-
sistent air-quality framework for integration 
with other benefits analyses. However, with-
out concentration–response functions, this 
approach still does not provide quantified 
health impacts or economic benefits.
• Expand benefits assessment efforts to include 
equity considerations. As noted earlier, there is 
an emerging literature on addressing equity 
considerations in addition to traditional 
analyses of efficiency. These approaches use 
statistical measures of inequality to deter-
mine the change in the population distri-
bution of air toxic risks. These changes in 
equity can then be compared with changes 
in total public health benefits to identify 
possible complementarities in health bene-
fits and equity or the tradeoffs between 
health benefits and equity.
Conclusions
The workshop provided new perspectives 
on benefits assessment of air toxics from 
participants with a wide range of expertise. 
Some key recommendations that emerged 
on moving forward on benefits assessment 
include the following:
• A clear definition of the purpose(s) of 
HAPs benefits analysis to frame long-term 
research priorities is needed. The near-term 
and long-term approaches would vary based 
on whether the focus should be on reduc-
ing air toxics for the general population, for 
hotspots and regions of interest, or for the 
most susceptible populations. A value-of-
information approach was recommended 
to prioritize future research based on what 
would have the greatest impact on benefit 
assessment outputs and what would reduce 
uncertainties most effectively.
• Grouping by emissions sources would 
address more closely the issue of hotspots 
or highly exposed populations, whereas 
grouping by chemical class would allow the 
use of toxicology and health data for well-
studied chemicals to inform those with more 
limited information but of similar structure 
or mode of action.
• Different population groups may be of 
particular concern for air toxics exposures, 
depending on the spatial and temporal dis-
tribution of exposures. Therefore, account-
ing for the heterogeneity in temporal and 
spatial distribution, specifically for emis-
sions and receptors (e.g., children and other 
vulnerable populations) is critical for bene-
fits analysis.
• The National Health and Nutrition 
Examination Survey work on exposure dis-
tributions could be used to inform both 
exposures and health end points (CDC 
2010).
• Analytical methods to define and meas-
ure equity considerations should be better 
  supported.
• There is a critical need to improve dose–
response estimations, potentially through 
use of models for probabilistic estimation of 
noncancer health risks.
• More research on surveillance and biomoni-
toring is needed to understand more fully 
how reductions in air toxics related to 
specific health effects.
• More support for research on the use of pre-
dictive biomarkers of exposure and health 
effects would allow for an early measurement 
of the impact in reduction of air toxics.
The above key recommendations provide 
some specific steps forward in advancing analysis 
of the benefits from air toxics reductions and 
suggest some future studies to inform many of 
the challenges in this field.
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